Access the full text.
Sign up today, get unlimited access with DeepDyve Pro!
infectious blood-borne diseases. Cost - effectiveness of Harm Reduction in Preventing Hepatitis C among Injection Drug Users Harold A. Pollack, PhD Objectives. Hepatitis C (HeV) has emerged as a major epi ...
to harm reduction and treatment for PWID is needed. Thanks to the development of safe and effective antiviral agents, eradication of the infection is now possible in almost all treated patients, leading ...
, this article relies on mathematical models to estimate the number of new HIV and hepatitis C virus infections prevented as a result of SIF locations in Toronto. After factoring in the costs associated with SIFs ...
Following the availability of highly effective direct-acting antivirals (DAAs) to treat hepatitis C infection, the uptake of treatment by people living with hepatitis C rose dramatically in high ...
BackgroundOpioid use is escalating in North America and comes with a multitude of health consequences, including HIV and hepatitis C virus (HCV) outbreaks among persons who inject drugs (PWID). HIV ...
. The literature search was done among articles related treatment of hepatitis C with DAAs in different patient groups with mass screening of the patients and cost benefit of new treatments as main key ...
the evidence for the effectiveness of primary prevention interventions to reduce incidence or prevalence of hepatitis C . Methods Systematic review of the major electronic medical databases: Medline, EMBASE ...
evaluate the cost - effectiveness of SSP alone, MOUD alone, and SSP + MOUD combination in preventing HCV cases among opioid IDUs in the United States.METHODS:We used a decision tree analysis model based ...
employment status . However, until recently, the evidence for OST or any harm reduction intervention reducing the risk of hepatitis C virus (HCV) acquisition was classified as insufficient . This situation ...
Needs. Rockville, MD: Agency for Healthcare Research and Quality; January 2013. 6. Rein DB, Smith BD, Wittenborn JS, et al. The cost - effectiveness of birth-cohort screening for hepatitis C antibody in US ...
Access the full text.
Sign up today, get unlimited access with DeepDyve Pro!